{"filing":{"accession_number":"0001711279-26-000058","cik":"0001711279","ticker":"KRYS","company_name":"Krystal Biotech, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"krys-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/krys-20260803.htm"},"events":[{"id":23456,"run_id":21207,"accession_number":"0001711279-26-000058","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results for the period ended June 30, 2026. The filing reports $119.2 million in product revenue (24% YoY growth), net income of $54.8 million ($1.85 per share basic), and a strong balance sheet with $1.1 billion in cash and investments. The press release is attached as Exhibit 99.1 and incorporated by reference, which is the typical structure for Item 2.02 earnings disclosures.","company_name":"Krystal Biotech, Inc.","ticker":"KRYS","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23685,"accession_number":"0001711279-26-000058","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results for the period ended June 30, 2026. The filing reports $119.2 million in product revenue (24% YoY growth), net income of $54.8 million ($1.85 per share basic), and a strong balance sheet with $1.1 billion in cash and investments. The press release is attached as Exhibit 99.1 and incorporated by reference, which is the typical structure for Item 2.02 earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:30.309895+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23685,"accession_number":"0001711279-26-000058","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results for the period ended June 30, 2026. The filing reports $119.2 million in product revenue (24% YoY growth), net income of $54.8 million ($1.85 per share basic), and a strong balance sheet with $1.1 billion in cash and investments. The press release is attached as Exhibit 99.1 and incorporated by reference, which is the typical structure for Item 2.02 earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:30.309895+00:00","company_name":"Krystal Biotech, Inc.","ticker":"KRYS","filing_date":"2026-08-03"}]}